Search research articles
Contact Us
Filters
Showing results (581-590 of 839) with videos related to
Page
of 84
Sort By:
European Urology
|
February 27, 2025
Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study
Stephen J Freedland, John P Mulhall, Martin Gleave, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 3, 2007
Standard treatments induce antigen-specific immune responses in prostate cancer
Nancy J Nesslinger, Robert A Sahota, Brad Stone, et al.
Translational Oncology
|
February 13, 2013
The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression
Khalil A Choucair, Karl-Philippe Guérard, Joshua Ejdelman, et al.
Frontiers in Oncology
|
February 18, 2021
Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics
Victor M Matias-Barrios, Mariia Radaeva, Yi Song, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
January 5, 2013
Inhibition of HSP27 blocks fibrosis development and EMT features by promoting Snail degradation
Guillaume Wettstein, Pierre-Simon Bellaye, Martin Kolb, et al.
Cancer Research
|
June 4, 2008
ASAP1, a gene at 8q24, is associated with prostate cancer metastasis
Dong Lin, Akira Watahiki, Jane Bayani, et al.
European Urology
|
May 20, 2014
Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies
Nader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès, et al.
Cancer Cell
|
March 23, 2013
The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity
Jianfei Qi, Manisha Tripathi, Rajeev Mishra, et al.
Biomaterials
|
October 22, 2011
Tissue uptake of docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols and their effects on the morphology of the bladder urothelium
Clement Mugabe, Peter A Raven, Ladan Fazli, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 27, 2011
Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer
Janessa J Laskin, Garth Nicholas, Christopher Lee, et al.
Page
of 84
Search research articles
Search
Showing results (581-590 of 839) with videos related to
Sort By:
Page
of 84
European Urology
|
February 27, 2025
Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study
Stephen J Freedland, John P Mulhall, Martin Gleave, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 3, 2007
Standard treatments induce antigen-specific immune responses in prostate cancer
Nancy J Nesslinger, Robert A Sahota, Brad Stone, et al.
Translational Oncology
|
February 13, 2013
The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression
Khalil A Choucair, Karl-Philippe Guérard, Joshua Ejdelman, et al.
Frontiers in Oncology
|
February 18, 2021
Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics
Victor M Matias-Barrios, Mariia Radaeva, Yi Song, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
January 5, 2013
Inhibition of HSP27 blocks fibrosis development and EMT features by promoting Snail degradation
Guillaume Wettstein, Pierre-Simon Bellaye, Martin Kolb, et al.
Cancer Research
|
June 4, 2008
ASAP1, a gene at 8q24, is associated with prostate cancer metastasis
Dong Lin, Akira Watahiki, Jane Bayani, et al.
European Urology
|
May 20, 2014
Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies
Nader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès, et al.
Cancer Cell
|
March 23, 2013
The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity
Jianfei Qi, Manisha Tripathi, Rajeev Mishra, et al.
Biomaterials
|
October 22, 2011
Tissue uptake of docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols and their effects on the morphology of the bladder urothelium
Clement Mugabe, Peter A Raven, Ladan Fazli, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 27, 2011
Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer
Janessa J Laskin, Garth Nicholas, Christopher Lee, et al.
Page
of 84